Schena Writes (one of) the Books on Protein Microarrays
Mark Schena’s fourth book on microarrays, Protein Microarrays, will be available on April 15, at a US list price of $88.95. The 450-page book is being published by Jones & Bartlett Publishers of Sudbury, Mass., a reference and textbook publisher. Previously, Schena has written Microarray Analysis (200), Microarray BioChip Technology (2000), and DNA Microarrays, A Practical Approach (1999). The book appears to be one of a wave of books on protein microarrays that will appear this spring. According to a search of the Amazon.com website, other protein microarray books in the pipeline include: Protein Microarray Technology, edited by Dev Kambhampati and scheduled for release this week by Wiley Europe ($125 list price). Kambhampati is the research and development officer of Industry-University Cooperative Research Program, a Berkeley, Calif., collaboration between the University of California, the industry, and the state of California. Also scheduled for release is Protein Arrays: Methods and Protocols, edited by Eric Fung, Humana Press; (April 2004), and listing for $99.50.
SAS and Bristol-Myers Squibb Engage in Gene-Expression Collaboration
SAS and Bristol-Myers Squibb will engage in a three-month pilot project using components of the SAS Scien-tific Discovery Solutions platform, the company announced last week.
Bristol-Myers will use SAS microarray and research data management applications to co-develop statistical methods for analyzing gene-expression data. Financial details of the collaboration were not disclosed.
Euro Commission to rule On GE Purchase of Amersham
The European Commission was scheduled to clear or extend its investigation of General Electric’s $9.5 billion proposed acquisition of Amersham on Jan. 21. The European regulatory body is expected to approve the deal, which received US regulatory approval in December.
Offered for License
The National Institutes of Health is offering for license, Combinatorial Therapy for Protein Signaling Diseases, a set of methods for individualizing therapy based on information obtained concerning deranged signaling pathways that cause disease. The invention includes the use of protein microarrays to detect the deranged signaling pathways that are specific for the subject’s disease. The invention covers the use of combination therapy targeting multiple points in the protein network. The researchers of record on the methods include Arpita Mehta and Lance Liotta of the National Cancer Institute, and Emmanuel Petricoin of the US Food and Drug Administration. The listings were published in the Federal Register on Jan. 5, 2004.
The conference, Chip Technologies: Microarrays, Hygiene and Health, is scheduled for Frankfurt, Germany, on Jan. 26-27 at DECHEMA-Haus. Keynote speakers include Panos Deloukas of the Human Genetics Group of the Sanger Institute and Guido Sauter of the Institute for Pathology and Urologic Clinics, University of Basel, Switzerland.
BioForce Nanosciences’ ViriChip Detects, ID’s Coxsackie Viruses
BioForce Nanosciences of Ames, Iowa, has developed the ViriChip, a technology that combines atomic force microscopy with solid phase affinity capture of biological entities for the detection and identification of certain viruses.
In a paper published in the Jan. 19 edition of the Institute of Physics journal, Nanotechnology, Saju Nettikadan of BioForce, and co-authors from Iowa State University and Des Moines University, describe the ViriChip and its application in detecting six different strains of a virus called coxsackievirus B, which some suspect as a key factor in deaths after organ transplants in humans. The ViriChip is a 6-mm silicon chip with antibodies printed on the surface. The viruses that attach to the antibodies are detected using an atomic force microscope.
CombiMatrix and Washington University to Create Libraries on Chips
Researchers at Washington University in St. Louis will use microarrays from CombiMatrix, a subsidiary of Acacia Research, to develop chip-based molecular libraries, the company announced this week.
Researchers, led by Kevin Moeller, plan to synthesize libraries of non-nucleic acid molecules onto CombiMatrix’s microarray technology, a system of electrochemically and independently addressable microelectrodes on semiconductor chips.